Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab as a rescue measure in COVID-19 (COVIDSTORM)
NCT04577534Phase 3Completed
- Start
- Aug 2020
- Primary completion
- Jun 2021
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tocilizumab in coronavirus disease 2019 (COVID-19). Started Aug 2020; status: completed.
02
Drugs
tocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04577534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04577534.